PMID- 19874253
OWN - NLM
STAT- MEDLINE
DCOM- 20100125
LR  - 20181201
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 10
IP  - 16
DP  - 2009 Nov
TI  - Vildagliptin in clinical practice: a review of literature.
PG  - 2745-57
LID - 10.1517/14656560903302265 [doi]
AB  - Vildagliptin is the second member of the DPP-IV inhibitor class of drugs licensed 
      for the treatment of type 2 diabetes mellitus (T2DM). The novel action of these 
      drugs has promoted a new outlook in the pathobiology of T2DM. This review 
      undertakes to examine the clinical studies published to date, with the aim of 
      evaluating the position of vildagliptin among the drugs that are now available to 
      treat this common dysmetabolic state.
FAU - Banerjee, Moulinath
AU  - Banerjee M
AD  - Central Manchester University Hospitals Foundation Trust, Department of Medicine, 
      Manchester, M13 9WL, UK.
FAU - Younis, Naveed
AU  - Younis N
FAU - Soran, Handrean
AU  - Soran H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Nitriles)
RN  - 0 (Pyrrolidines)
RN  - I6B4B2U96P (Vildagliptin)
RN  - PJY633525U (Adamantane)
SB  - IM
MH  - Adamantane/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use
MH  - Blood Glucose/analysis
MH  - Diabetes Mellitus, Type 2/drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/pharmacokinetics/pharmacology/*therapeutic use
MH  - Humans
MH  - Islets of Langerhans/drug effects
MH  - Nitriles/pharmacokinetics/pharmacology/*therapeutic use
MH  - Pyrrolidines/pharmacokinetics/pharmacology/*therapeutic use
MH  - Vildagliptin
RF  - 79
EDAT- 2009/10/31 06:00
MHDA- 2010/01/26 06:00
CRDT- 2009/10/31 06:00
PHST- 2009/10/31 06:00 [entrez]
PHST- 2009/10/31 06:00 [pubmed]
PHST- 2010/01/26 06:00 [medline]
AID - 10.1517/14656560903302265 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2009 Nov;10(16):2745-57. doi: 
      10.1517/14656560903302265.